Key facts
- This page summarizes Paul A. Laviolette's Form 4 filing for PULSE BIOSCIENCES, INC. (PLSE).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Jan 2025, 19:45.
Paul A. Laviolette - 09 Jan 2025 Form 4 Insider Report for PULSE BIOSCIENCES, INC. (PLSE)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- PLSE
- Reported as of
- 09 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jan 2025, 19:45:33 UTC
- Prior SEC filing
- 13 Aug 2024
- Next SEC filing
- 09 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kenneth B. Stratton, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paul A. Laviolette filed Form 4 for PULSE BIOSCIENCES, INC. (PLSE) on 13 Jan 2025.
Change
- Previous filing in this sequence was filed on 13 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PLSE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +450,000
- Change %
- Price
- $0.000000
- Shares after
- 450,000
- Date
- 09 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 450,000
- Exercise price
- $18.43
- Footnotes
- F1
PLSE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +1,050,000
- Change %
- Price
- $0.000000
- Shares after
- 1,050,000
- Date
- 09 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,050,000
- Exercise price
- $18.43
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
One-fourth of the shares subject to the option will vest on the three-year anniversary of the grant and the remaining shares will vest on the four-year anniversary of the grant, subject to the Reporting Person's continued service through each vesting date.
Footnote F2
The shares subject to this option are subject to five tranches of performance-based vesting criteria tied to certain operating targets and the Issuer's market capitalization ranging from $3 billion to $9 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.